Patents Assigned to Hanmi Pharm. Co., Ltd.
  • Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
    Patent number: 10946003
    Abstract: Disclosed is a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation, based on considerably improved pH-dependent drug release characteristics, starts to release the esomeprazole or a pharmaceutically acceptable salt thereof at a target delay time after oral administration, continues the release for a predetermined time, and finishes the release after a predetermined time, thereby providing excellent patient convenience and excellent therapeutic effects, as compared to conventional other formulations.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: March 16, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Taek Kwan Kwon, Kwang Young Lee, Ho Taek Im, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • IGG4 FC FRAGMENT COMPRISING MODIFIED HINGE REGION
    Publication number: 20210060129
    Abstract: A modified IgG4 Fc fragment useful as a drug carrier is disclosed. When coupled to a drug, the resulting drug-IgG4 Fc conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.
    Type: Application
    Filed: November 13, 2020
    Publication date: March 4, 2021
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Sung Youb JUNG, Yong Ho Huh, Sung Hee Park, Jong Soo Lee, In Young Choi
  • Conjugate of therapeutic enzymes
    Patent number: 10918736
    Abstract: The present invention relates to a conjugate in which an immunoglobulin Fc region is linked to therapeutic enzymes through a non-peptide polymer linkage moiety, and more specifically, to a conjugate in which a non-peptide polymer linkage moiety is specifically linked to an immunoglobulin Fc, a method of preparing the same, and a composition comprising the same.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: February 16, 2021
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Dae Jin Kim, Jung Kuk Kim, Sung Youb Jung, Se Chang Kwon
  • Long-acting insulin or insulin analogue conjugate
    Patent number: 10894089
    Abstract: The present invention relates to insulin and/or an insulin analogue conjugate, and a use thereof, wherein the insulin and/or insulin analogue have improved in vivo durability and stability by linking the same with an Fc region of immunoglobulin. The insulin and/or an insulin analogue conjugate of the present invention show an in vivo activity similar to that of insulin. In addition, the insulin and/or insulin analogue conjugate of the present invention are long-acting formulations of insulin and/or the analogue thereof, in which serum half-life is remarkably increased, and therefore, the present invention provides remarkable insulin and/or an insulin analogue conjugate, which do not induce hypoglycemia, a drawback of insulin treatment.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: January 19, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Yong Ho Heo, Jong Soo Lee, Sung Hee Park, Dae Jin Kim, Sung Youb Jung, Se Chang Kwon
  • THERAPEUTIC ENZYME FUSION PROTEIN HAVING A NOVEL STRUCTURE AND USE THEREOF
    Publication number: 20210009984
    Abstract: A fusion protein of a dimeric therapeutic enzyme and an immunoglobulin Fc region, a preparation method thereof, and a composition containing the fusion protein are disclosed.
    Type: Application
    Filed: December 21, 2018
    Publication date: January 14, 2021
    Applicant: Hanmi Pharm. Co., Ltd.
    Inventors: Eui Joon JUNG, Jin Young KIM, In Young CHOI, Sung Youb JUNG
  • PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF
    Publication number: 20210009591
    Abstract: Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 14, 2021
    Applicant: Hanmi Pharm. Co., Ltd.
    Inventors: In Hwan BAE, Ji Sook KIM, Won Jeoung KIM, Chang Hee PARK, Ji Young SONG, Young Gil AHN
  • Glucagon derivatives with improved stability
    Patent number: 10881715
    Abstract: The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: January 5, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk Kim, Jong Min Lee, Sang Yun Kim, Sung Min Bae, Sung Youb Jung, Se Chang Kwon
  • Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
    Patent number: 10870639
    Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: December 22, 2020
    Assignee: HANMI PHARM. CO.. LTD.
    Inventors: In Hwan Bae, Ji Sook Kim, Jae Yul Choi, Seok Jong Kang, Young Gil Ahn, Kwee Hyun Suh
  • BIOMARKER INDICATING RESPONSE TO POZIOTINIB THERAPY FOR CANCER
    Publication number: 20200370102
    Abstract: Provided are biomarkers that are sensitive or resistant to poziotinib therapy for cancer and methods of using the biomarkers.
    Type: Application
    Filed: November 14, 2018
    Publication date: November 26, 2020
    Applicants: HANMI PHARM. CO., LTD., NATIONAL CANCER CENTER, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Yeon Hee PARK, Kyung Hee PARK, Eun Jin LEE, Woong Yang PARK, Min Chae KIM, Young Whan PARK, Jung Yong KIM
  • PHARMACEUTICAL COMPOSITION INCLUDING MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND SPHEROIDAL PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND METHOD OF PREPARING THE PHARMACEUTICAL COMPOSITION
    Publication number: 20200368219
    Abstract: Provided are a pharmaceutical composition including a core in a form of a multi-unit spheroidal tablet (MUST) containing esomeprazole or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is dissolved by 50 percent (%) or more within 15 minutes of an in vitro dissolution test; and a method of preparing the pharmaceutical composition. According to this, in case that the pharmaceutical composition is developed as the multi-unit spheroidal tablet, the dissolution may be accelerated in a condition of a slow stirring rate than that of a conventional pellet formulation or single tablet. Also, proton pump inhibitors (PPI)-based drugs including esomeprazole may be dissociated by gastric acid having a low pH, consequently inducing a decrease in bioavailability of the drug, but the pharmaceutical composition according to this may be minimize this.
    Type: Application
    Filed: September 28, 2018
    Publication date: November 26, 2020
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Hyuk Jun CHO, Min Wook KIM, Ho Taek IM, Yong II KIM
  • ANTI-PD-L1/ANTI-PD-1 NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMERIC BISPECIFIC ANTIBODY AND PREPARATION THEREOF
    Publication number: 20200299412
    Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.
    Type: Application
    Filed: March 28, 2018
    Publication date: September 24, 2020
    Applicant: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Mengxie Jin
  • LONG ACTING PROTEIN COMPLEX HAVING AN ENHANCED EFFICIENCY
    Publication number: 20200283492
    Abstract: The present invention relates to a protein complex, in which a physiologically active polypeptide modified with a fatty acid molecule and an immunoglobulin Fc region are linked through a non-peptide polymer linker, a pharmaceutical composition comprising the same, and a method for preparing the protein complex. The protein complex extends the blood half-life of the physiologically active polypeptide through the linkage of the binding site of immunoglobulin. Fc and the intramolecular bonding of the fatty acid molecule; has an excellent in vivo activity; and has no risk of inducing an immune response.
    Type: Application
    Filed: October 1, 2018
    Publication date: September 10, 2020
    Applicant: HANMI PHARM CO., LTD.
    Inventors: Jong-Soo LEE, Eun Jung KIM, Dae Jin KIM
  • NOVEL METHOD FOR PREPARING (2R)-2-(2-METHOXYPHENYL)-2-(OXANE-4-YLOXY)ETHANE-1-OL COMPOUND, AND INTERMEDIATE USED THEREIN
    Publication number: 20200283401
    Abstract: A novel method for preparing a compound of Chemical Formula 1 is disclosed. The method includes a step of obtaining a compound of Chemical Formula 1 by performing a reduction reaction on a compound of Chemical Formula 2; and an intermediate used therein.
    Type: Application
    Filed: September 27, 2018
    Publication date: September 10, 2020
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Wook JANG, Jong Ouk BAEK, Hee Cheol KIM, Tae Hee HA
  • CRYSTALLINE FORMS OF HYDROCHLORIDE SALTS OF THIENOPYRIMIDINE COMPOUND
    Publication number: 20200270268
    Abstract: The present invention relates to a crystalline form of a hydrochloride salt of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and a pharmaceutical composition containing the same. The crystalline form of the hydrochloride salt of the compound can be easily used for preparing a pharmaceutical composition containing the same as an active ingredient.
    Type: Application
    Filed: December 30, 2016
    Publication date: August 27, 2020
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jong Ouk BAEK, Ji Young JEON, Hee Sook OH, Hee Cheol KIM, Sun Young JANG, Tae Hee HA
  • LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES
    Publication number: 20200262888
    Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.
    Type: Application
    Filed: March 27, 2020
    Publication date: August 20, 2020
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jaehyuk CHOI, Min Young KIM, In Young CHOI, Sung Youb JUNG
  • PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME
    Publication number: 20200255410
    Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: In Hwan BAE, Ji Sook KIM, Jae Yul CHOI, Seok Jong KANG, Young Gil AHN, Kwee Hyun SUH
  • LONG-ACTING SINGLE-CHAIN INSULIN ANALOG AND CONJUGATE THEREOF
    Publication number: 20200254108
    Abstract: The present invention relates to a long-acting single-chain insulin analog, a conjugate thereof, and uses of the same. In addition, the present invention relates to a method for preparing a long-acting single-chain insulin analog and a conjugate thereof.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 13, 2020
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Yong Ho HEO, Euh Lim OH
  • LONG-ACTING CONJUGATE OF A PHYSIOLOGICALLY ACTIVE MATERIAL AND USE THEREOF
    Publication number: 20200230250
    Abstract: The present invention relates to a conjugate including a physiologically active material, a linker, and a material capable of increasing in vivo half-life of the physiologically active material, a method for preparing the same, and a preparation thereof.
    Type: Application
    Filed: February 2, 2018
    Publication date: July 23, 2020
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Young Jin PARK, Jong-Soo LEE, In Young CHOI
  • GLUCAGON DERIVATIVE AND A COMPOSITION COMPRISING A LONG ACTING CONJUGATE OF THE SAME
    Publication number: 20200223897
    Abstract: A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 16, 2020
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk KIM, Young Jin PARK, In Young CHOI, Sung Youb JUNG
  • Glucagon derivative and a composition comprising a long acting conjugate of the same
    Patent number: 10696725
    Abstract: The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: June 30, 2020
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk Kim, Young Jin Park, In Young Choi, Sung Youb Jung